Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in korean patients with major depression

Yong Gu Kim, Hun Soo Chang, Eun Soo Won, Byung-Joo Ham, Min-Soo Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: The genetic variations in serotonin-related genes may be associated with antidepressant treatment response in major depressive disorder (MDD). The tryptophan hydroxylase-1 (TPH1) gene and serotonin 5A receptor (HTR5A) gene are known to be involved in serotonin biosynthesis and signal transduction, respectively. The purpose of this study was to investigate a possible interaction between the TPH1 gene and the HTR5A gene in the treatment outcome of escitalopram in MDD. Methods: In total, 245 patients diagnosed with MDD were recruited, and their symptoms were evaluated using the 17-item Hamilton Depression Rating scale (HAMD-17). The association between the TPH1 218A/C and HTR5A 12A/T polymorphisms and the clinical outcomes (remission, response and changes in HAMD-17 score) was investigated after 2, 4 and 8 weeks of escitalopram treatment using multiple logistic regression or multiple linear regression analysis. Results: No significant associations of TPH1 or HTR5A gene polymorphisms were observed with either response rate or remission rate at 2, 4 and 8 weeks after escitalopram treatment. In addition, the gene-gene interaction between TPH1 and HTR5A genes was not associated with the treatment outcome. Conclusions: Our results suggest that TPH1 218A/C and HTR5A 12A/T polymorphisms cannot predict treatment response in major depression.

Original languageEnglish
Pages (from-to)210-219
Number of pages10
JournalNeuropsychobiology
Volume69
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Tryptophan Hydroxylase
Citalopram
Serotonin
Depression
Genes
Major Depressive Disorder
Therapeutics
Antidepressive Agents
Linear Models
Signal Transduction
Logistic Models
Regression Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Biological Psychiatry

Cite this

Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in korean patients with major depression. / Kim, Yong Gu; Chang, Hun Soo; Won, Eun Soo; Ham, Byung-Joo; Lee, Min-Soo.

In: Neuropsychobiology, Vol. 69, No. 4, 01.01.2014, p. 210-219.

Research output: Contribution to journalArticle

@article{485a953f7cee4a408d9fb6dd692dd6ae,
title = "Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in korean patients with major depression",
abstract = "Background/Aims: The genetic variations in serotonin-related genes may be associated with antidepressant treatment response in major depressive disorder (MDD). The tryptophan hydroxylase-1 (TPH1) gene and serotonin 5A receptor (HTR5A) gene are known to be involved in serotonin biosynthesis and signal transduction, respectively. The purpose of this study was to investigate a possible interaction between the TPH1 gene and the HTR5A gene in the treatment outcome of escitalopram in MDD. Methods: In total, 245 patients diagnosed with MDD were recruited, and their symptoms were evaluated using the 17-item Hamilton Depression Rating scale (HAMD-17). The association between the TPH1 218A/C and HTR5A 12A/T polymorphisms and the clinical outcomes (remission, response and changes in HAMD-17 score) was investigated after 2, 4 and 8 weeks of escitalopram treatment using multiple logistic regression or multiple linear regression analysis. Results: No significant associations of TPH1 or HTR5A gene polymorphisms were observed with either response rate or remission rate at 2, 4 and 8 weeks after escitalopram treatment. In addition, the gene-gene interaction between TPH1 and HTR5A genes was not associated with the treatment outcome. Conclusions: Our results suggest that TPH1 218A/C and HTR5A 12A/T polymorphisms cannot predict treatment response in major depression.",
keywords = "Escitalopram treatment response, Major depressive disorder, Serotonin 5A receptor, Tryptophan hydroxylase-1",
author = "Kim, {Yong Gu} and Chang, {Hun Soo} and Won, {Eun Soo} and Byung-Joo Ham and Min-Soo Lee",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000362241",
language = "English",
volume = "69",
pages = "210--219",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in korean patients with major depression

AU - Kim, Yong Gu

AU - Chang, Hun Soo

AU - Won, Eun Soo

AU - Ham, Byung-Joo

AU - Lee, Min-Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/Aims: The genetic variations in serotonin-related genes may be associated with antidepressant treatment response in major depressive disorder (MDD). The tryptophan hydroxylase-1 (TPH1) gene and serotonin 5A receptor (HTR5A) gene are known to be involved in serotonin biosynthesis and signal transduction, respectively. The purpose of this study was to investigate a possible interaction between the TPH1 gene and the HTR5A gene in the treatment outcome of escitalopram in MDD. Methods: In total, 245 patients diagnosed with MDD were recruited, and their symptoms were evaluated using the 17-item Hamilton Depression Rating scale (HAMD-17). The association between the TPH1 218A/C and HTR5A 12A/T polymorphisms and the clinical outcomes (remission, response and changes in HAMD-17 score) was investigated after 2, 4 and 8 weeks of escitalopram treatment using multiple logistic regression or multiple linear regression analysis. Results: No significant associations of TPH1 or HTR5A gene polymorphisms were observed with either response rate or remission rate at 2, 4 and 8 weeks after escitalopram treatment. In addition, the gene-gene interaction between TPH1 and HTR5A genes was not associated with the treatment outcome. Conclusions: Our results suggest that TPH1 218A/C and HTR5A 12A/T polymorphisms cannot predict treatment response in major depression.

AB - Background/Aims: The genetic variations in serotonin-related genes may be associated with antidepressant treatment response in major depressive disorder (MDD). The tryptophan hydroxylase-1 (TPH1) gene and serotonin 5A receptor (HTR5A) gene are known to be involved in serotonin biosynthesis and signal transduction, respectively. The purpose of this study was to investigate a possible interaction between the TPH1 gene and the HTR5A gene in the treatment outcome of escitalopram in MDD. Methods: In total, 245 patients diagnosed with MDD were recruited, and their symptoms were evaluated using the 17-item Hamilton Depression Rating scale (HAMD-17). The association between the TPH1 218A/C and HTR5A 12A/T polymorphisms and the clinical outcomes (remission, response and changes in HAMD-17 score) was investigated after 2, 4 and 8 weeks of escitalopram treatment using multiple logistic regression or multiple linear regression analysis. Results: No significant associations of TPH1 or HTR5A gene polymorphisms were observed with either response rate or remission rate at 2, 4 and 8 weeks after escitalopram treatment. In addition, the gene-gene interaction between TPH1 and HTR5A genes was not associated with the treatment outcome. Conclusions: Our results suggest that TPH1 218A/C and HTR5A 12A/T polymorphisms cannot predict treatment response in major depression.

KW - Escitalopram treatment response

KW - Major depressive disorder

KW - Serotonin 5A receptor

KW - Tryptophan hydroxylase-1

UR - http://www.scopus.com/inward/record.url?scp=84901733153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901733153&partnerID=8YFLogxK

U2 - 10.1159/000362241

DO - 10.1159/000362241

M3 - Article

VL - 69

SP - 210

EP - 219

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 4

ER -